Literature DB >> 26079345

Practice Patterns and Outcomes Associated With Choice of Initial Vasopressor Therapy for Septic Shock.

Ashraf Fawzy1, Stephen R Evans, Allan J Walkey.   

Abstract

OBJECTIVES: Clinical guidelines recommend norepinephrine as initial vasopressor of choice for septic shock, with dopamine suggested as an alternative vasopressor in selected patients with low risk of tachyarrhythmias and absolute or relative bradycardia. We sought to determine practice patterns and outcomes associated with vasopressor selection in a large, population-based cohort of patients with septic shock that allows for assessment of outcomes in clinically important subgroups.
DESIGN: We performed a retrospective cohort study to determine factors associated with choice of dopamine as compared with norepinephrine as initial vasopressor for patients with septic shock. We used propensity score matching to compare risk of hospital mortality based on initial vasopressor. We performed multiple sensitivity analyses using alternative methods to address confounding and hospital-level clustering. We investigated interaction between vasopressor selection and mortality in clinical subgroups based on arrhythmia and cardiovascular risk.
SETTING: Enhanced administrative data (Premier, Charlotte, NC) from 502 U.S. hospitals during the years 2010-2013.
SUBJECTS: A total of 61,122 patients admitted with septic shock who received dopamine or norepinephrine as initial vasopressor during the first 2 days of hospitalization.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Norepinephrine (77.6%) was the most frequently used initial vasopressor during septic shock. Dopamine was preferentially selected by cardiologists, in the Southern United States, at nonteaching hospitals, for older patients with more cardiovascular comorbidities and was used less frequently over time. Patients receiving dopamine experienced greater hospital mortality (propensity-matched cohort: n = 38,788; 25% vs 23.7%; odds ratio, 1.08; 95% CI, 1.02-1.14). Sensitivity analyses showed similar results. Subgroup analyses showed no evidence for effect modification based on arrhythmia risk or underlying cardiovascular disease.
CONCLUSIONS: In a large population-based sample of patients with septic shock in the United States, use of dopamine as initial vasopressor was associated with increased mortality among multiple clinical subgroups. Areas where use of dopamine as initial vasopressor is more common represent potential targets for quality improvement intervention.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26079345      PMCID: PMC5094367          DOI: 10.1097/CCM.0000000000001149

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  17 in total

1.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

2.  A randomized trial of protocol-based care for early septic shock.

Authors:  Donald M Yealy; John A Kellum; David T Huang; Amber E Barnato; Lisa A Weissfeld; Francis Pike; Thomas Terndrup; Henry E Wang; Peter C Hou; Frank LoVecchio; Michael R Filbin; Nathan I Shapiro; Derek C Angus
Journal:  N Engl J Med       Date:  2014-03-18       Impact factor: 91.245

3.  Association between source of infection and hospital mortality in patients who have septic shock.

Authors:  Aleksandra Leligdowicz; Peter M Dodek; Monica Norena; Hubert Wong; Aseem Kumar; Anand Kumar
Journal:  Am J Respir Crit Care Med       Date:  2014-05-15       Impact factor: 21.405

4.  Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis*.

Authors:  Daniel De Backer; Cesar Aldecoa; Hassane Njimi; Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2012-03       Impact factor: 7.598

5.  Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study.

Authors:  Yasser Sakr; Konrad Reinhart; Jean-Louis Vincent; Charles L Sprung; Rui Moreno; V Marco Ranieri; Daniel De Backer; Didier Payen
Journal:  Crit Care Med       Date:  2006-03       Impact factor: 7.598

6.  Comparison of dopamine and norepinephrine in the treatment of shock.

Authors:  Daniel De Backer; Patrick Biston; Jacques Devriendt; Christian Madl; Didier Chochrad; Cesar Aldecoa; Alexandre Brasseur; Pierre Defrance; Philippe Gottignies; Jean-Louis Vincent
Journal:  N Engl J Med       Date:  2010-03-04       Impact factor: 91.245

7.  Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.

Authors:  Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali
Journal:  Med Care       Date:  2005-11       Impact factor: 2.983

8.  Identifying patients with severe sepsis using administrative claims: patient-level validation of the angus implementation of the international consensus conference definition of severe sepsis.

Authors:  Theodore J Iwashyna; Andrew Odden; Jeffrey Rohde; Catherine Bonham; Latoya Kuhn; Preeti Malani; Lena Chen; Scott Flanders
Journal:  Med Care       Date:  2014-06       Impact factor: 2.983

9.  The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis.

Authors:  P E Marik; M Mohedin
Journal:  JAMA       Date:  1994-11-02       Impact factor: 56.272

10.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.

Authors:  R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno
Journal:  Intensive Care Med       Date:  2013-01-30       Impact factor: 17.440

View more
  6 in total

1.  Epidemiology of Vasopressin Use for Adults with Septic Shock.

Authors:  Emily A Vail; Hayley B Gershengorn; May Hua; Allan J Walkey; Hannah Wunsch
Journal:  Ann Am Thorac Soc       Date:  2016-10

2.  Practice patterns and complication rates of thrombolysis for pulmonary embolism.

Authors:  Mark A Bradford; Peter K Lindenauer; Allan J Walkey
Journal:  J Thromb Thrombolysis       Date:  2016-10       Impact factor: 2.300

3.  Association Between Hospital Case Volume of Sepsis, Adherence to Evidence-Based Processes of Care and Patient Outcomes.

Authors:  Ashraf Fawzy; Allan J Walkey
Journal:  Crit Care Med       Date:  2017-06       Impact factor: 7.598

4.  Practice Patterns in the Initiation of Secondary Vasopressors and Adjunctive Corticosteroids during Septic Shock in the United States.

Authors:  Nicholas A Bosch; Bijan Teja; Hannah Wunsch; Allan J Walkey
Journal:  Ann Am Thorac Soc       Date:  2021-12

Review 5.  Efficacy and Safety of Vasopressin Alone or in Combination With Catecholamines in the Treatment of Septic Shock: A Systematic Review.

Authors:  Naishal Mandal; Nang I Kham; Rabia Shahid; Shaili S Naik; Shivana Ramphall; Swarnima Rijal; Vishakh Prakash; Heba Ekladios; Jiya Mulayamkuzhiyil Saju; Sathish Venugopal
Journal:  Cureus       Date:  2022-09-14

6.  Mortality Associated with Severe Sepsis Among Age-Similar Women with and without Pregnancy-Associated Hospitalization in Texas: A Population-Based Study.

Authors:  Lavi Oud
Journal:  Med Sci Monit       Date:  2016-06-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.